Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Biomarker for Diagnosis and Monitoring of Treatment Response in Major Depressive Disorder: Changes in Serum L‐Glutamine Levels

Title: Biomarker for Diagnosis and Monitoring of Treatment Response in Major Depressive Disorder: Changes in Serum L‐Glutamine Levels
Authors: Lee, Seungyeon; Lee, You‐Rim; Mun, Sora; Yun, Yeeun; Kang, Hee‐Gyoo; Lee, Jiyeong
Contributors: National Research Foundation of Korea
Source: Biomedical Chromatography ; volume 39, issue 9 ; ISSN 0269-3879 1099-0801
Publisher Information: Wiley
Publication Year: 2025
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: Major depressive disorder (MDD) is a mood disorder that causes serious functional impairment. Existing diagnostic methods rely on subjective assessments because of its complex and heterogeneous pathophysiology; therefore, development of objective biomarkers is urgently needed. To control the high heterogeneity of MDD, a pairwise design in which depressed and remitted states of the same patient were paired to minimize the influence of intrinsic factors was introduced, and serum metabolite changes between states were analyzed using non‐targeted and targeted metabolomics approaches. State‐based biomarkers that could be used for objective diagnosis of MDD were identified, and their clinical applicability was validated in an expanded study group. L‐Glutamine was selected because it showed a tendency to increase during the remitted state. Through multiple reaction monitoring‐based quantitative verification, L‐glutamine levels significantly increased in the remitted state compared with those in the depressed state, regardless of the influence of drug treatment, proving its potential as a diagnostic marker. This study identified differences in serum metabolites in patients with MDD using a metabolomic approach; L‐glutamine could be used as a promising biomarker to distinguish between depressive and remissive states. These results can contribute to the precise diagnosis of MDD and establishment of personalized treatment strategies.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1002/bmc.70197
Availability: https://doi.org/10.1002/bmc.70197; https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/bmc.70197
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.AD7EB8D6
Database: BASE